These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Neoadjuvant chemoradiation is associated with decreased lymph node ratio in borderline resectable pancreatic cancer: A propensity score matched analysis. Peng JS; Morris-Stiff G; Ali NS; Wey J; Chalikonda S; El-Hayek KM; Walsh RM Hepatobiliary Pancreat Dis Int; 2021 Feb; 20(1):74-79. PubMed ID: 32861576 [TBL] [Abstract][Full Text] [Related]
3. Significance of neoadjuvant therapy for borderline resectable pancreatic cancer: a multicenter retrospective study. Kurahara H; Shinchi H; Ohtsuka T; Miyasaka Y; Matsunaga T; Noshiro H; Adachi T; Eguchi S; Imamura N; Nanashima A; Sakamoto K; Nagano H; Ohta M; Inomata M; Chikamoto A; Baba H; Watanabe Y; Nishihara K; Yasunaga M; Okuda K; Natsugoe S; Nakamura M Langenbecks Arch Surg; 2019 Mar; 404(2):167-174. PubMed ID: 30649607 [TBL] [Abstract][Full Text] [Related]
4. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma. Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715 [TBL] [Abstract][Full Text] [Related]
5. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival. Rose JB; Rocha FG; Alseidi A; Biehl T; Moonka R; Ryan JA; Lin B; Picozzi V; Helton S Ann Surg Oncol; 2014 May; 21(5):1530-7. PubMed ID: 24473642 [TBL] [Abstract][Full Text] [Related]
6. Clinical Characteristics of Patients Experiencing Pathologic Complete Response Following Neoadjuvant Therapy for Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma. Hashemi-Sadraei N; Gbolahan OB; Salfity H; O'Neil B; House MG; Shahda S Am J Clin Oncol; 2018 Oct; 41(10):982-985. PubMed ID: 28968257 [TBL] [Abstract][Full Text] [Related]
7. Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy and neoadjuvant stereotactic body radiotherapy. Mellon EA; Jin WH; Frakes JM; Centeno BA; Strom TJ; Springett GM; Malafa MP; Shridhar R; Hodul PJ; Hoffe SE Acta Oncol; 2017 Mar; 56(3):391-397. PubMed ID: 27885876 [TBL] [Abstract][Full Text] [Related]
8. Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery. Barnes CA; Chavez MI; Tsai S; Aldakkak M; George B; Ritch PS; Dua K; Clarke CN; Tolat P; Hagen C; Hall WA; Erickson BA; Evans DB; Christians KK Surgery; 2019 Sep; 166(3):277-285. PubMed ID: 31272811 [TBL] [Abstract][Full Text] [Related]
9. Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy. Christians KK; Heimler JW; George B; Ritch PS; Erickson BA; Johnston F; Tolat PP; Foley WD; Evans DB; Tsai S Surgery; 2016 Mar; 159(3):893-900. PubMed ID: 26602840 [TBL] [Abstract][Full Text] [Related]
10. Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: Is radiation necessary in the modern era of chemotherapy? Kim SS; Nakakura EK; Wang ZJ; Kim GE; Corvera CU; Harris HW; Kirkwood KS; Hirose R; Tempero MA; Ko AH J Surg Oncol; 2016 Oct; 114(5):587-596. PubMed ID: 27444658 [TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant docetaxel-based chemoradiation for resectable adenocarcinoma of the pancreas: New neoadjuvant regimen was safe and provided an interesting pathologic response. Turrini O; Ychou M; Moureau-Zabotto L; Rouanet P; Giovannini M; Moutardier V; Azria D; Delpero JR; Viret F Eur J Surg Oncol; 2010 Oct; 36(10):987-92. PubMed ID: 20828979 [TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant Therapy Followed by Resection Versus Upfront Resection for Resectable Pancreatic Cancer: A Propensity Score Matched Analysis. Mokdad AA; Minter RM; Zhu H; Augustine MM; Porembka MR; Wang SC; Yopp AC; Mansour JC; Choti MA; Polanco PM J Clin Oncol; 2017 Feb; 35(5):515-522. PubMed ID: 27621388 [TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: An intention to treat analysis. Barenboim A; Lahat G; Geva R; Nachmany I; Nakache R; Goykhman Y; Brazowski E; Rosen G; Isakov O; Wolf I; Klausner JM; Lubezky N Eur J Surg Oncol; 2018 Oct; 44(10):1619-1623. PubMed ID: 30146251 [TBL] [Abstract][Full Text] [Related]
14. Clinical Impact of Neoadjuvant Chemotherapy and Chemoradiotherapy in Borderline Resectable Pancreatic Cancer: Analysis of 884 Patients at Facilities Specializing in Pancreatic Surgery. Nagakawa Y; Sahara Y; Hosokawa Y; Murakami Y; Yamaue H; Satoi S; Unno M; Isaji S; Endo I; Sho M; Fujii T; Takishita C; Hijikata Y; Suzuki S; Kawachi S; Katsumata K; Ohta T; Nagakawa T; Tsuchida A Ann Surg Oncol; 2019 Jun; 26(6):1629-1636. PubMed ID: 30610555 [TBL] [Abstract][Full Text] [Related]
15. Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention-to-treat analysis. Sugimoto M; Takahashi N; Farnell MB; Smyrk TC; Truty MJ; Nagorney DM; Smoot RL; Chari ST; Carter RE; Kendrick ML J Surg Oncol; 2019 Nov; 120(6):976-984. PubMed ID: 31452208 [TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant Therapy is Associated with Improved Survival in Borderline-Resectable Pancreatic Cancer. Chawla A; Molina G; Pak LM; Rosenthal M; Mancias JD; Clancy TE; Wolpin BM; Wang J Ann Surg Oncol; 2020 Apr; 27(4):1191-1200. PubMed ID: 31802297 [TBL] [Abstract][Full Text] [Related]
17. Does pre-operative chemoradiation for initially unresectable or borderline resectable pancreatic adenocarcinoma increase post-operative morbidity? A case-matched analysis. Araujo RL; Gaujoux S; Huguet F; Gonen M; D'Angelica MI; DeMatteo RP; Fong Y; Kingham TP; Jarnagin WR; Goodman KA; Allen PJ HPB (Oxford); 2013 Aug; 15(8):574-80. PubMed ID: 23458208 [TBL] [Abstract][Full Text] [Related]
18. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma. Mellon EA; Hoffe SE; Springett GM; Frakes JM; Strom TJ; Hodul PJ; Malafa MP; Chuong MD; Shridhar R Acta Oncol; 2015 Jul; 54(7):979-85. PubMed ID: 25734581 [TBL] [Abstract][Full Text] [Related]
19. Five-Year Actual Overall Survival in Resected Pancreatic Cancer: A Contemporary Single-Institution Experience from a Multidisciplinary Perspective. Picozzi VJ; Oh SY; Edwards A; Mandelson MT; Dorer R; Rocha FG; Alseidi A; Biehl T; Traverso LW; Helton WS; Kozarek RA Ann Surg Oncol; 2017 Jun; 24(6):1722-1730. PubMed ID: 28054192 [TBL] [Abstract][Full Text] [Related]
20. Correlation of clinical and pathological staging and response to neoadjuvant therapy in resected pancreatic cancer. Mirkin KA; Greenleaf EK; Hollenbeak CS; Wong J Int J Surg; 2018 Apr; 52():221-228. PubMed ID: 29425826 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]